Cariprazine (Reagila®) for the treatment of schizophrenia
The Minister of Health, Welfare and Sport (WVS) asked the National Health Care Institute (National Health Care Institute) to carry out a substantive assessment of the medicinal product Reagila® to determine whether it can be included in the Medicine Reimbursement System (GVS). And if so, if Cariprazine (Reagila®) is interchangeable with a medicinal product that is already included in the GVS.
Advice
Reagila® is an atypical antipsychotic, registered for the treatment of schizophrenia in adult patients. Based on the criteria for interchangeability, the National Health Care Institute concludes that Reagila® is interchangeable with drugs that are already included in cluster 4N05AEAO of the GVS. This cluster contains eight atypical antipsychotics: aripiprazole (Abilify®), lurasidone (Latuda®), olanzapine (Zyprexa®), paliperidone (Invega®), quetiapine (Seroquel®), risperidone (Risperdal®), sertindole (Serdolect®) and sulpiride.
We advise the Minister to include cariprazine (Reagila®) in List 1A of the GVS, in cluster 4N05AEAO.
This report is a summary of recommendations by the National Health Care Institute. The original text of this excerpt is in Dutch.